you are here: Home News Molnupiravir

Molnupiravir

Molnupiravir does not cut deaths in high risk Covid patients: Lancet study
Divi’s Labs: Steady margin profile amid cost headwind
Hetero finds positive results from Molnupiravir third phase trials
Molnupiravir more effective against Omicron, claims new study
New antiviral drug combo highly effective against COVID-19: Study
Laurus Labs: Diversification away from ARVs on track
Dr Reddy’s: Supported by traction in limited competition products
Natco Pharma gets non-exclusive licence to manufacture, sell anti-COVID pill Molnupiravir
Molnupiravir not included in COVID-19 treatment guidelines as its harms outweigh benefits : Health Ministry
Divi’s Lab: Green chemistry can set it apart
Covid-19 | Molnupiravir shows more gains than risks, say experts
India to become hub for COVID-19 antiviral generic drugs: Fitch
Lupin launches Molnulup for COVID-19 treatment
Aurobindo Pharma launches COVID-19 drug Molnupiravir in India
Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment
Emcure Pharmaceuticals to launch anti-Covid pill in week
Mankind, BDR Pharma join hands to launch anti COVID-19 pill Molulife
Cipla gets EUA from DCGI to market Molnupiravir for COVID-19 treatment
Corbevax, Covovax, Molnupiravir approved for restricted emergency use against COVID-19
COVID-19: Is the hype around the oral drug Molnupiravir justified?
UK authorizes Merck antiviral pill, 1st shown to treat COVID-19
Dr Reddy’s: Growth story remains intact; margins key monitorable
Sun Pharma: Traction in speciality likely to sustain
Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term
Lupin: Focus on inhalation and bio-similars to aid margins in medium term

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Molnupiravir

Molnupiravir does not cut deaths in high risk Covid patients: Lancet study

Divi’s Labs: Steady margin profile amid cost headwind

Hetero finds positive results from Molnupiravir third phase trials

Molnupiravir more effective against Omicron, claims new study

New antiviral drug combo highly effective against COVID-19: Study

Laurus Labs: Diversification away from ARVs on track

Dr Reddy’s: Supported by traction in limited competition products

Natco Pharma gets non-exclusive licence to manufacture, sell anti-COVID pill Molnupiravir

Molnupiravir not included in COVID-19 treatment guidelines as its harms outweigh benefits : Health Ministry

Divi’s Lab: Green chemistry can set it apart

Covid-19 | Molnupiravir shows more gains than risks, say experts

India to become hub for COVID-19 antiviral generic drugs: Fitch

Lupin launches Molnulup for COVID-19 treatment

Aurobindo Pharma launches COVID-19 drug Molnupiravir in India

Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment

Emcure Pharmaceuticals to launch anti-Covid pill in week

Mankind, BDR Pharma join hands to launch anti COVID-19 pill Molulife

Cipla gets EUA from DCGI to market Molnupiravir for COVID-19 treatment

Corbevax, Covovax, Molnupiravir approved for restricted emergency use against COVID-19

COVID-19: Is the hype around the oral drug Molnupiravir justified?

UK authorizes Merck antiviral pill, 1st shown to treat COVID-19

Dr Reddy’s: Growth story remains intact; margins key monitorable

Sun Pharma: Traction in speciality likely to sustain

Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term

Lupin: Focus on inhalation and bio-similars to aid margins in medium term